265 629

Cited 41 times in

Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model

DC Field Value Language
dc.contributor.author이용호-
dc.contributor.author고영국-
dc.contributor.author김중선-
dc.contributor.author김병극-
dc.contributor.author장양수-
dc.contributor.author홍명기-
dc.contributor.author최동훈-
dc.contributor.author이승준-
dc.contributor.author이오현-
dc.contributor.author오재원-
dc.contributor.author전옥희-
dc.contributor.author홍성진-
dc.contributor.author박세일-
dc.contributor.author안철민-
dc.date.accessioned2020-09-28T11:34:20Z-
dc.date.available2020-09-28T11:34:20Z-
dc.date.issued2020-05-
dc.identifier.issn1738-5520-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/179231-
dc.description.abstractBackground and objectives: We sought to investigate an anti-atherosclerotic and anti-inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model. Methods: Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet for 7 weeks followed by normal diet for 2 weeks. After balloon catheter injury, the rabbits were administered with the Dapagliflozin (1mg/kg/day) or control-medium for 8 weeks (n=13 for each group). All lesions were assessed with angiography, optical coherence tomography (OCT), and histological assessment. Results: Atheroma burden (38.51±3.16% vs. 21.91±1.22%, p<0.01) and lipid accumulation (18.90±3.63% vs. 10.20±2.03%, p=0.047) was significantly decreased by SGLT-2 inhibitor treatment. The SGLT-2 inhibitor group showed lower macrophage infiltration (20.23±1.89% vs. 12.72±1.95%, p=0.01) as well as tumor necrosis factor (TNF)-α expression (31.17±4.40% vs. 19.47±2.10%, p=0.025). Relative area of inducible nitric oxide synthase⁺ macrophages was tended to be lower in the SGLT-2 inhibitor-treated group (1.00±0.16% vs. 0.71±0.10%, p=0.13), while relative proportion of Arg1⁺ macrophage was markedly increased (1.00±0.27% vs. 2.43±0.64%, p=0.04). As a result, progression of atherosclerosis was markedly attenuated in SGLT-2 inhibitor treated group (OCT area stenosis, 32.13±1.20% vs. 22.77±0.88%, p<0.01). Mechanistically, SGLT-2 treatment mitigated the inflammatory responses in macrophage. Especially, Toll-like receptor 4/nuclear factor-kappa B signaling pathway, and their downstream effectors such as interleukin-6 and TNF-α were markedly suppressed by SGLT-2 inhibitor treatment. Conclusions: These results together suggest that SGLT-2 inhibitor exerts an anti-atherosclerotic effect through favorable modulation of inflammatory response as well as macrophage characteristics in non-diabetic situation.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish, Korean-
dc.publisherKorean Society of Circulation-
dc.relation.isPartOfKOREAN CIRCULATION JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleAnti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSeul Gee Lee-
dc.contributor.googleauthorSeung Jun Lee-
dc.contributor.googleauthorJung Jae Lee-
dc.contributor.googleauthorJung Sun Kim-
dc.contributor.googleauthorOh Hyun Lee-
dc.contributor.googleauthorChoong Ki Kim-
dc.contributor.googleauthorDarae Kim-
dc.contributor.googleauthorYong Ho Lee-
dc.contributor.googleauthorJaewon Oh-
dc.contributor.googleauthorSeil Park-
dc.contributor.googleauthorOk Hee Jeon-
dc.contributor.googleauthorSung Jin Hong-
dc.contributor.googleauthorChul Min Ahn-
dc.contributor.googleauthorByeong Keuk Kim-
dc.contributor.googleauthorYoung Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorMyeong Ki Hong-
dc.contributor.googleauthorYangsoo Jang-
dc.identifier.doi10.4070/kcj.2019.0296-
dc.contributor.localIdA02989-
dc.contributor.localIdA00127-
dc.contributor.localIdA00961-
dc.contributor.localIdA00493-
dc.contributor.localIdA03448-
dc.contributor.localIdA04391-
dc.contributor.localIdA04053-
dc.contributor.localIdA05648-
dc.relation.journalcodeJ01952-
dc.identifier.eissn1738-5555-
dc.identifier.pmid32153145-
dc.subject.keywordAtherosclerosis-
dc.subject.keywordMacrophages-
dc.subject.keywordSodium-glucose transporter 2 inhibitors-
dc.subject.keywordSodium-glucose transporter-2-
dc.contributor.alternativeNameLee, Yong Ho-
dc.contributor.affiliatedAuthor이용호-
dc.contributor.affiliatedAuthor고영국-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor장양수-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor최동훈-
dc.citation.volume50-
dc.citation.number5-
dc.citation.startPage443-
dc.citation.endPage457-
dc.identifier.bibliographicCitationKOREAN CIRCULATION JOURNAL, Vol.50(5) : 443-457, 2020-05-
dc.identifier.rimsid67439-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.